Ellacor Micro-Coring: The Device That Removes Skin Without Leaving a Scar

Every wrinkle treatment on the market makes the same bargain. Fillers add volume beneath the line. Neurotoxins stop the muscle that folds it. Lasers and radiofrequency injure the skin so the repair response rebuilds it. All of them work around the actual problem, which is blunt and mechanical: as skin ages, there is too much of it for the frame underneath.

A facelift solves that by cutting the excess away — and trading it for an incision, general anesthesia, and weeks of recovery. Ellacor proposes something stranger. It removes the excess skin too. It just does it 6,000 tiny pieces at a time, and somehow leaves nothing behind to see.

The loophole: why 0.5 millimeters changes everything

The reason surgeons cannot simply excise skin without a scar comes down to a threshold in wound healing. Above a certain wound width, the body repairs with fibrosis — disorganized collagen laid down fast, which is what a scar is. Below that width, skin closes and regenerates without fibrotic tissue.

Above a certain wound width, the body repairs with fibrosis — disorganized collagen laid down fast, which is what a scar is.

Micro-coring lives underneath that threshold. The device uses a hollow 22-gauge needle — an internal diameter of roughly 410 micrometers, under half a millimeter — to punch out full-thickness cores containing both epidermis and dermis, which are then removed by suction. No heat is involved anywhere in the process. Nothing is burned, coagulated, or ablated. Tissue is simply taken out and discarded.

Do it once and you have a pinprick. Do it six thousand times across a cheek, removing roughly 7 to 8 percent of the skin’s surface area, and you have excised a meaningful quantity of skin — with every individual wound narrow enough to heal without a scar.

The histology backs the claim rather than merely asserting it. A 2025 study of treated abdominal skin found preserved elastic fiber distribution and no histologically visible scar formation at any depth examined, up to 7 millimeters, with the epidermis intact throughout. The same study found a robust increase in new collagen deposition after one to three treatments compared with untreated control skin in every subject — roughly 25 to 50 percent more collagen fibers in one cohort and 50 to 100 percent in another [1].

So the device does two things at once: it subtracts surface area, and the healing response adds collagen.

What the pivotal trial actually showed

Ellacor’s FDA clearance rests on a trial of 51 subjects, 98% women, mean age 62.9, treated on the mid and lower face. They received up to three sessions spaced a month apart, with coring at depths of 3 to 5 millimeters and a minimum of 6,000 micro-cores per treatment.

Mean improvement on the Lemperle Wrinkle Severity Scale was 1.3 grades. Independent assessment found improvement at 89.7% of treated sites, and 85.6% of sites met patient satisfaction. Pain averaged between 1.2 and 2.8 on a ten-point scale, and average downtime was three days. Four mild-to-moderate adverse device effects were recorded — a black eye, numbness, redness, and visible needle marks — with no serious adverse events [2].

Earlier safety work across three prospective trials had already established the core mechanism. Pain was comparable to microneedling, and on facial skin registered between 0 and 0.4 out of 10. Treated skin showed a statistically significant increase in thickness versus controls. And at a 10% treatment density, facial surface area shrank by an average of 9.4% — the tightening effect, measured directly rather than inferred from photographs. There was no clinical or histologic scarring [3].

A 2024 matched-cohort study went further, comparing 13 micro-coring patients against 13 who had a facelift alone. The micro-coring group achieved measurable philtrum shortening averaging 1.07 millimeters, while the facelift-only controls showed no significant change. Perioral elasticity and wrinkles improved significantly relative to controls [4].

That last finding is worth sitting with. On one specific measure, in one small retrospective study, a needle-based office procedure outperformed surgery.

The limits nobody puts on the brochure

The clearance language is narrower than the marketing. Ellacor is cleared for moderate to severe wrinkles in the mid and lower face, in adults 22 and older, with Fitzpatrick skin types I to IV. Types V and VI are outside the cleared indication, and the pivotal trial population was overwhelmingly Fitzpatrick II to III [2]. If you have deeply pigmented skin, the evidence base does not yet include you — which is a real gap, not a technicality.

The trial population also tells you who this is for. Mean age 62.9, moderate to severe wrinkles. This is not a preventative treatment or a subtle refresher. If your concern is early nasolabial folds or mild skin laxity, you are not the person this device was studied on, and gentler options carry better evidence for your situation.

And then there is the arithmetic. Removing 8 percent of your facial skin three times is a finite operation. You cannot repeat it forever — there is only so much skin, and each session takes real tissue away permanently. Whatever Ellacor buys you, it buys once, or a small number of times.

What happens on day four

Three days of downtime, then you rejoin your life with less skin and more collagen than you had a month ago. And then the process that created the problem picks up exactly where it left off.

Three days of downtime, then you rejoin your life with less skin and more collagen than you had a month ago.

Research from the University of Michigan mapped the mechanism. Fibroblasts from donors over 80 produced markedly less type I procollagen than those from donors aged 18 to 29. Aged skin also showed a smaller share of the fibroblast surface attached to collagen fibers — meaning the cells receive weaker mechanical signals instructing them to build [5]. Fewer workers, and a broken intercom telling them what to make.

Micro-coring does not repair that. It performs an elegant subtraction and triggers a burst of healing collagen, then hands you back the same aging machinery. The device buys you back some years of accumulated excess. It does not slow the rate at which you accumulate more.

The other side of the equation

Subtraction is one half of the problem. Production is the other, and it is the half you control daily.

In a randomized, vehicle-controlled trial, topical retinol applied to naturally aged skin over 24 weeks significantly reduced fine wrinkles versus vehicle — and did it by increasing glycosaminoglycan expression and type I collagen production in the treated tissue [6]. That is intervention at the level of the fibroblast: not removing the evidence of low collagen production, but raising the production itself.

Which makes a retinoid the natural complement to a device like this rather than a competitor. Ellacor addresses the accumulated past. A retinoid addresses the ongoing present.

Retinol’s historic problem has been getting in. The molecule is unstable and the skin barrier exists specifically to exclude foreign compounds, so conventional formulas rely on solvents and penetration enhancers that disrupt the barrier’s lipid structure to force the active through. That mechanism — damaging the barrier to deliver the payload — is the source of retinol’s reputation for redness and peeling.

Nanoretinol solves the delivery problem instead of muscling past it. Retinol is encapsulated in biomimetic lipid nanoparticles externally similar to the skin’s own cells, so the barrier recognizes them as “self” and lets them through intact — the same class of nanotechnology used in modern drug delivery. North Biomedical’s clinical study found this approach 232% more effective than conventional retinol at collagen recovery and 73% more effective at elastin recovery, with a 61% increase in skin firmness over 56 days [7]. The concentration is 0.2%, because once delivery works, concentration stops being the variable that matters.

For skin recovering from a procedure that just removed 6,000 cores of tissue, an active that arrives without picking a fight with the barrier is not a nicety. It is the difference between a routine you keep and one you abandon.

The honest summary

Ellacor is the most conceptually interesting device in aesthetics right now, and the evidence supporting it is real: measurable surface-area reduction, verified collagen increases, no scarring on histology, and a pivotal trial with no serious adverse events. If you are in your sixties with moderate to severe mid-face wrinkles and Fitzpatrick I to IV skin, it is a legitimate option worth a consultation. If you are considering a non-surgical face lift, it belongs on the list.

But a device that works by removing skin is, by definition, a treatment with a floor. You get a small number of sessions across a lifetime. What you do in the years between them — and in the decades before you ever consider one — is not the supporting act. It is the main event, and it has always been decided by what you put on your skin every night.

References

1. Bhatia AC, Napekoski K, Edgecombe J, Weir D, Winkle R, Rohrich R. “Histologic Study of Abdominal Skin Treated With Mechanical Dermal Micro-Coring Technology for Minimally Invasive Skin Removal.” Journal of Cosmetic Dermatology. 2025;24(7):e70323. doi:10.1111/jocd.70323
2. Gfrerer L, Kilmer SL, Waibel JS, Geronemus RG, Biesman BS. “Dermal Micro-coring for the Treatment of Moderate to Severe Facial Wrinkles.” Plastic and Reconstructive Surgery Global Open. 2022;10(10):e4547. doi:10.1097/GOX.0000000000004547
3. Pozner JN, Kilmer SL, Geronemus RG, Jack M, Burns JA, Kaminer MS. “Cytrellis: A Novel Microcoring Technology for Scarless Skin Removal: Summary of Three Prospective Clinical Trials.” Plastic and Reconstructive Surgery Global Open. 2021;9(10):e3905. doi:10.1097/GOX.0000000000003905
4. Carruthers KH, Vyas K, Remy K, McCarty JC, Austen WG Jr. “Micro-Coring: A Novel Approach to Perioral Rejuvenation.” Aesthetic Surgery Journal. 2024;44(11):1209-1217. doi:10.1093/asj/sjae120
5. Varani J, Dame MK, Rittié L, Fligiel SEG, Kang S, Fisher GJ, Voorhees JJ. “Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation.” American Journal of Pathology. 2006;168(6):1861-1868. doi:10.2353/ajpath.2006.051302
6. Kafi R, Kwak HSR, Schumacher WE, Cho S, Hanft VN, Hamilton TA, King AL, Neal JD, Varani J, Fisher GJ, Voorhees JJ, Kang S. “Improvement of naturally aged skin with vitamin A (retinol).” Archives of Dermatology. 2007;143(5):606-612. doi:10.1001/archderm.143.5.606
7. North Biomedical LLC. “Nanoretinol vs. Conventional Retinol: Efficacy in Collagen and Elastin Recovery.” Clinical Study Summary, 2024. Study summary